Studying Patient Participation Patterns in Treatment Resistant Depression
Observes how often adults with treatment resistant depression finish or leave studies.
Plain-language title generated from the registry record
Registry title: Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients
Key facts
- Where
- San Francisco, United StatesSee the site
Where in United States
- Power Life SciencesSan Francisco, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Power Life Sciences Inc.
- Trial code
- NCT06101914
- Record updated
- 26 October 2023
- Original description
Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption.Read full original descriptionShow less
Evaluating the Occurrence of Engagement Patterns and Participation Trends Among Patients in Treatment Resistant Depression
Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption.
The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.
Inclusion: Diagnosis of treatment resistant depression; Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed; No prior treatment for treatment resistant depression.
Exclusion: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; Enrolled in another research study; Inability to provide written informed consent.